Oct. 3 at 10:55 PM
$KLTO
KLTO holds patents in the United States, Europe, and China for s Klotho gene therapies targeting not only ALS but also major neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.
This shows that alpha Klotho based treatments are being developed with dementia indications in mind. Although KLTO-202 is currently focused on ALS, its restoration of alpha Klotho signaling provides a solid scientific foundation for later expanding its use to Alzheimer’s and other dementias.
Current other drugs on the market typically use single target antibodies to remove either amyloid or tau, whereas KLTO-202 activates both clearance pathways simultaneously for more comprehensive removal of pathological aggregates. This approach is sure to draw strong interest from the dementia treatment community.
Imagine a dementia treatment strategy that combines self healing at the gene and protein levels with traditional drug therapy.
